Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage.

[1]  C. Blobel,et al.  Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding , 2002, Inflammation Research.

[2]  C. Little,et al.  ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. , 2005, Arthritis and rheumatism.

[3]  K. Shimizu,et al.  Mature bovine articular cartilage contains abundant aggrecan that is C-terminally truncated at Ala719-Ala720, a site which is readily cleaved by m-calpain. , 2004, The Biochemical journal.

[4]  H. Ma,et al.  Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. , 2004, Arthritis and rheumatism.

[5]  A. Dorner,et al.  ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[6]  S. Apte.  A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. , 2004, The international journal of biochemistry & cell biology.

[7]  A. Grodzinsky,et al.  Mechanical Compression of Cartilage Explants Induces Multiple Time-dependent Gene Expression Patterns and Involves Intracellular Calcium and Cyclic AMP* , 2004, Journal of Biological Chemistry.

[8]  Ping Wang,et al.  Proprotein Convertase Furin Interacts with and Cleaves Pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi Network* , 2004, Journal of Biological Chemistry.

[9]  J. Sandy,et al.  ADAMTS4 (Aggrecanase-1) Activation on the Cell Surface Involves C-terminal Cleavage by Glycosylphosphatidyl Inositol-anchored Membrane Type 4-Matrix Metalloproteinase and Binding of the Activated Proteinase to Chondroitin Sulfate and Heparan Sulfate on Syndecan-1* , 2004, Journal of Biological Chemistry.

[10]  J. Enghild,et al.  Altered Proteolytic Activities of ADAMTS-4 Expressed by C-terminal Processing* , 2004, Journal of Biological Chemistry.

[11]  J. Foidart,et al.  Crystal structure of the catalytic domain of MMP-16/MT3-MMP: characterization of MT-MMP specific features. , 2004, Journal of molecular biology.

[12]  James P. Quigley,et al.  Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer , 2003, Cancer and Metastasis Reviews.

[13]  B. Martinac,et al.  Effects of long-term exposure to glucosamine and mannosamine on aggrecan degradation in articular cartilage. , 2003, Osteoarthritis and cartilage.

[14]  V. Quesada,et al.  Identification and Characterization of ADAMTS-20 Defines a Novel Subfamily of Metalloproteinases-Disintegrins with Multiple Thrombospondin-1 Repeats and a Unique GON Domain* , 2003, The Journal of Biological Chemistry.

[15]  R. Leduc,et al.  Characterization of ADAMTS-9 and ADAMTS-20 as a Distinct ADAMTS Subfamily Related to Caenorhabditis elegans GON-1* , 2003, The Journal of Biological Chemistry.

[16]  P. Scherle,et al.  Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. , 2003, Arthritis and rheumatism.

[17]  E. Lavallie,et al.  Autocatalytic Cleavage of ADAMTS-4 (Aggrecanase-1) Reveals Multiple Glycosaminoglycan-binding Sites* , 2002, The Journal of Biological Chemistry.

[18]  T. Burn,et al.  Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[19]  E. Lavallie,et al.  ADAMTS4 Cleaves at the Aggrecanase Site (Glu373-Ala374) and Secondarily at the Matrix Metalloproteinase Site (Asn341-Phe342) in the Aggrecan Interglobular Domain* , 2002, The Journal of Biological Chemistry.

[20]  J. Sandy,et al.  Activation of the Proteolytic Activity of ADAMTS4 (Aggrecanase-1) by C-terminal Truncation* , 2002, The Journal of Biological Chemistry.

[21]  R. Berk,et al.  Expression of membrane-type matrix metalloproteinases 4, 5, and 6 in mouse corneas infected with P. aeruginosa. , 2001, Investigative ophthalmology & visual science.

[22]  M. Tortorella,et al.  The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. , 2001, Osteoarthritis and cartilage.

[23]  G. de Nanteuil,et al.  Effects of ceramide on aggrecanase activity in rabbit articular cartilage. , 2001, Biochemical and biophysical research communications.

[24]  J. Fischer,et al.  Versican V1 Proteolysis in Human Aorta in Vivo Occurs at the Glu441-Ala442 Bond, a Site That Is Cleaved by Recombinant ADAMTS-1 and ADAMTS-4* , 2001, The Journal of Biological Chemistry.

[25]  A. Rowan,et al.  Esculetin inhibits cartilage resorption induced by interleukin 1α in combination with oncostatin M , 2001, Annals of the rheumatic diseases.

[26]  J. Sandy.  Proteoglycan core proteins and catabolic fragments present in tissues and fluids. , 2001, Methods in molecular biology.

[27]  J. Sandy,et al.  Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. , 2001, The Biochemical journal.

[28]  K. Matsushima,et al.  ADAMTS‐1 cleaves a cartilage proteoglycan, aggrecan , 2000, FEBS letters.

[29]  P. Patwari,et al.  Mannosamine inhibits aggrecanase-mediated changes in the physical properties and biochemical composition of articular cartilage. , 2000, Archives of biochemistry and biophysics.

[30]  Y. Itoh,et al.  Membrane Type 4 Matrix Metalloproteinase (MT4-MMP, MMP-17) Is a Glycosylphosphatidylinositol-anchored Proteinase* , 1999, The Journal of Biological Chemistry.

[31]  R. D. Dyer,et al.  Catalytic Activities and Substrate Specificity of the Human Membrane Type 4 Matrix Metalloproteinase Catalytic Domain* , 1999, The Journal of Biological Chemistry.

[32]  J. Sandy,et al.  Chondrocyte-mediated catabolism of aggrecan: evidence for a glycosylphosphatidylinositol-linked protein in the aggrecanase response to interleukin-1 or retinoic acid. , 1999, Archives of biochemistry and biophysics.

[33]  V. Ganu,et al.  Matrix Metalloproteinase Inhibitor CGS 27023A Protects COMP and Proteoglycan in the Bovine Articular Cartilage but not the Release of Their Fragments from Cartilage after Prolonged Stimulation in Vitro with IL‐1α , 1999, Annals of the New York Academy of Sciences.

[34]  T. Saito,et al.  Esculetin suppresses proteoglycan metabolism by inhibiting the production of matrix metalloproteinases in rabbit chondrocytes. , 1999, European journal of pharmacology.

[35]  J. Trzăskos,et al.  Generation and Characterization of Aggrecanase , 1999, The Journal of Biological Chemistry.

[36]  L. Lohmander,et al.  Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. , 1999, The Journal of rheumatology.

[37]  J. Sandy,et al.  Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. , 1998, The Biochemical journal.

[38]  B. Caterson,et al.  Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. , 1998, Osteoarthritis and cartilage.

[39]  J. Kollár,et al.  Complete coding sequence of bovine aggrecan: comparative structural analysis. , 1997, Archives of biochemistry and biophysics.

[40]  L. Bonassar,et al.  Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors. , 1997, Archives of biochemistry and biophysics.

[41]  N. Borkakoti,et al.  Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors. , 1997, The Biochemical journal.

[42]  A. Grodzinsky,et al.  A molecular model of proteoglycan-associated electrostatic forces in cartilage mechanics. , 1995, Journal of biomechanical engineering.

[43]  A. Barrett,et al.  Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. , 1993, Arthritis and rheumatism.

[44]  Teizo Fujita,et al.  Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria , 1993, Cell.

[45]  L. Lohmander,et al.  The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. , 1992, The Journal of clinical investigation.

[46]  Mark C. Field,et al.  Mannosamine, a novel inhibitor of glycosylphosphatidylinositol incorporation into proteins. , 1991, The EMBO journal.

[47]  J. Sandy,et al.  Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. , 1991, The Journal of biological chemistry.

[48]  A. Grodzinsky,et al.  Biosynthetic response of cartilage explants to dynamic compression , 1989, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[49]  R. Smith,et al.  Properties of interleukin-1 as a complete secretagogue for human neutrophils. , 1985, Biochemical and biophysical research communications.